Summary Currently, well over 1,000 antibody Fab or Fab variable (Fv) structures have been
determined and deposited in the Protein Data Bank (www. rcsb. org). Many of these …

Abstract Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1)
gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are …

Dengue is a mosquito-borne flavivirus that is spreading at an unprecedented rate and has
developed into a major health and economic burden in over 50 countries. Even though …

Abstract The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1
acquisition. Plasma collected from HIV-1-uninfected trial participants completing all …

A number of antibodies that efficiently neutralize microbial targets contain long heavy chain
complementarity determining region 3 (HCDR3) loops. For HIV, several of the most broad …

INTRODUCTION It is widely believed that the development of an effective neutralizing
antibody–based HIV-1 vaccine will require consistent activation of multiple germline …

Development of an HIV vaccine is a global priority. A major roadblock to a vaccine is an
inability to induce protective broadly neutralizing antibodies (bnAbs). HIV gp41 bnAbs have …

Human immunodeficiency virus type 1 (HIV-1) vaccine development requires selection of
appropriate envelope (Env) immunogens. Twenty HIV-1 Env glycoproteins were examined …

Human parainfluenza virus type 3 (hPIV3) is a respiratory pathogen that can cause severe
disease in older people and infants. Currently, vaccines against hPIV3 are in clinical trials …

ABSTRACT SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated
into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion. HIV …